Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
- Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap
- Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support
- Together, Abbott and Bigfoot will continue to advance technology-driven solutions for making diabetes management even more personal and precise
ABBOTT PARK, Ill. and MILPITAS, Calif., Sept. 5, 2023 /PRNewswire/ — Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
